CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

amifampridine

Last Updated: November 23, 2020
Result type: Reports
Project Number: SR0660-000
Product Line: Reimbursement Review

Generic Name: amifampridine

Brand Name: Ruzurgi

Manufacturer: Médunik Canada Inc.

Therapeutic Area: Lambert-Eaton myasthenic syndrome

Indications: Indicated for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 years of age and older.

Manufacturer Requested Reimbursement Criteria1: Indicated for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 years of age and older.

Submission Type: Initial

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input openSeptember 08, 2020
Call for patient input closedOctober 28, 2020
Clarification:

- Patient input submission received from individual patient

Submission receivedOctober 05, 2020
Submission acceptedOctober 20, 2020
Review initiatedOctober 21, 2020
Clarification:

- Selected for CADTH/INESSS Joint Clinician Engagement

Draft CADTH review report(s) provided to sponsor for commentJanuary 11, 2021
Deadline for sponsors commentsJanuary 20, 2021
CADTH responses on draft review report(s) provided to sponsorMarch 05, 2021
Expert committee meeting (initial)March 17, 2021
Draft recommendation issued to sponsorMarch 29, 2021
To
March 31, 2021